Radioembolization for previously treated liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and weigh more than 30 kg (about 66 pounds).
- You need a diagnosis of liver cancer (hepatocellular carcinoma).
- You must have already had a treatment like TACE or HAIC (ways to block the tumor's blood supply and give chemo directly to the liver).
- Your liver function must be good enough (Child-Pugh score 7 or less), and you should be able to care for yourself (ECOG 0 or 1).
- Your cancer must be only in the liver, not spread to other parts of the body.
- If you have a clot in a major liver blood vessel (portal vein tumor thrombus), your doctor will need to check an imaging test to be sure it's safe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors through a tube. It is for people with one or a few small liver tumors that cannot be removed with surgery or destroyed with heat or cold. The goal is to shrink or control the tumors with fewer side effects.
This trial tests a targeted radiation treatment (radioembolization) for liver cancer that has grown into the main vein (portal vein) but is still limited to one lobe of the liver. It is for people who have not received any prior cancer treatment and whose liver function is still fairly good.
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.